Tamiflu: the battle for secret drug data

@article{Payne2012TamifluTB,
  title={Tamiflu: the battle for secret drug data},
  author={D. Payne},
  journal={BMJ : British Medical Journal},
  year={2012},
  volume={345}
}
  • D. Payne
  • Published 2012
  • Medicine
  • BMJ : British Medical Journal
  • Influenza drug oseltamivir has made billions of pounds for Roche, but why won’t the company give patients and doctors access to the full clinical data? As part of the BMJ’s open data campaign, we this week launch a new site dedicated to the cause. David Payne reports 
    19 Citations

    Topics from this paper

    The pioneers of transparency
    • B. Adams
    • Medicine
    • BMJ : British Medical Journal
    • 2015
    • 2
    Oseltamivir: over 15 years of data retention and systematic stonewalling.
    • Medicine
    • Prescrire international
    • 2016
    Medicines agency rejects a quarter of requests for documents it holds on drugs
    • 3
    The new BMJ policy on sharing data from drug and device trials
    • 60
    • PDF
    Clinical trial data for all drugs in current use
    • F. Godlee
    • Medicine
    • BMJ : British Medical Journal
    • 2012
    • 57
    • PDF

    References

    SHOWING 1-6 OF 6 REFERENCES
    Neuraminidase inhibitors—the story behind the Cochrane review
    • P. Doshi
    • Medicine
    • BMJ : British Medical Journal
    • 2009
    • 85
    • PDF
    WHO and the pandemic flu “conspiracies”
    • 167
    Point-by-point response from Roche to BMJ questions
    • J. Smith
    • Medicine
    • BMJ : British Medical Journal
    • 2009
    • 24
    Health minister agrees to meet academics to discuss access to clinical trial data
    • 5